title: Is there clinical value to prognostic signatures in early-stage NSCLC?
abstract: pAMPK and pmTOR favorably predicted outcome in early non-small cell lung cancer (NSCLC). The differences were small. Phosphoprotein lability makes routine clinical use and validation difficult. Protein immunohistochemistry is unlikely to be clinically useful, and numerous efforts to create predictive models to select resected patients for therapy have been unsuccessful.
authors.affiliation: Authors' Affiliations: Division of Medical Oncology, Departments of Medicine and Pathology, University of Colorado Cancer Center, University of Colorado Denver, Aurora, Colorado.
authors.forename: Paul A
authors.initials: PA
authors.lastname: Bunn
authors.forename: Fred R
authors.initials: FR
authors.lastname: Hirsch
authors.forename: Dara L
authors.initials: DL
authors.lastname: Aisner
mesh_terms: D055372:AMP-Activated Protein Kinases / Q000235:genetics / Q000378:metabolism*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D006801:Humans; D009367:Neoplasm Staging; D010766:Phosphorylation; D057285:Precision Medicine; D011237:Predictive Value of Tests; D011379:Prognosis; D058570:TOR Serine-Threonine Kinases / Q000235:genetics / Q000378:metabolism*
chemical_list: C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; D055372:AMP-Activated Protein Kinases